Since no studies deepened the potential role of PSMA-targeting PET in this clinical setting to date, prospective studies are warranted in order to overpower our diagnostic instruments as well as reach the goal of a truly tailored medicine in HCC patients. The gene discussed is FOLH1; the disease is hepatocellular carcinoma.